# ElevateBio

> ElevateBio is a privately held advanced therapy contract development and manufacturing organization that combines BaseCamp process development and cGMP manufacturing with Life Edit gene editing technologies and discovery services. It serves biotechnology, pharmaceutical and academic partners developing cell, gene and RNA therapies, with collaborations including Kyverna, Novo Nordisk, Moderna and AWS.

- **Founded:** 2017
- **Headquarters:** Waltham, United States
- **Founders:** David Hallal (Co-founder; Executive Chairman; former CEO), Vikas Sinha (Co-founder; board member; former CFO), Mitchell Finer (Co-founder; former Chief Scientific Officer)
- **Products:** BaseCamp, Life Edit, Gene Editing Design & Optimization, Cell therapy manufacturing, Viral vector and mRNA manufacturing
- **Notable:** Four disclosed financing rounds total USD 1.246 billion through May 2023., Reported 98% manufacturing batch success across cell therapy, viral vector and mRNA batches in 2025; this is an operational metric, not a clinical outcome., Reported sixth consecutive year of revenue growth in January 2026, without disclosing absolute revenue.

## Products & services

- **BaseCamp** — Process and analytical development, technology transfer, quality, regulatory CMC support and cGMP manufacturing for advanced therapies; Waltham flagship opened in 2020.
- **Life Edit** — Gene editing technologies and discovery services across nucleases, base editing, reverse transcriptase editing, targeted insertion and epigenetic editing; acquired in 2021.
- **Gene Editing Design & Optimization** — Proof-of-concept engagements delivering up to three gene editors for evaluation on a partner’s samples; company describes fixed deliverables and typical delivery within six months.
- **Cell therapy manufacturing** — Development and manufacturing for autologous and allogeneic CAR-T, TCR-T, TIL, Treg, NK, HSC and iPSC-derived programs.
- **Viral vector and mRNA manufacturing** — Lentiviral vector, AAV and mRNA therapeutic and vaccine development and manufacturing.
- **Viral and non-viral delivery technologies** — Vector engineering and lipid nanoparticle delivery capabilities supporting genetic medicine development.
- **AI-assisted protein discovery** — Protein language models and experimental screening to discover and optimize gene editing proteins; AWS collaboration announced in March 2025.

## Achievements

- Four disclosed financing rounds total USD 1.246 billion through May 2023.
- Reported 98% manufacturing batch success across cell therapy, viral vector and mRNA batches in 2025; this is an operational metric, not a clinical outcome.
- Reported sixth consecutive year of revenue growth in January 2026, without disclosing absolute revenue.
- Received multi-modality ICMC certification from Dark Horse Consulting in August 2025.
- Waltham BaseCamp won the 2021 ISPE Facility of the Year category award for Operational Excellence.
- Signed a commercial manufacturing and supply agreement for Kyverna’s investigational miv-cel in July 2026.

## Latest updates

- **2026-09** — Steven Falcone appointed COO, responsible for operations and quality as Waltham prepares for its first commercial product and Pittsburgh expansion progresses.
- **2026-07** — Kyverna and ElevateBio signed a manufacturing and supply agreement for miv-cel; Kyverna targeted completion of its rolling SPS BLA in Q4 2026.
- **2026-05** — ASGCT presentations covered targeted insertion, epigenetic editing, AI-designed editing proteins and preclinical LNP delivery data.
- **2026-01** — Christopher Murphy appointed CEO January 5, succeeding interim CEO Ger Brophy.
- **2026-01** — Company reported sixth consecutive annual revenue growth, 98% batch success in 2025 and Pittsburgh operations expected in 2027.

## Links

- Website: https://elevate.bio/
- LinkedIn: https://www.linkedin.com/company/elevatebio/
- Twitter/X: https://twitter.com/elevatebio

---

Profile page: https://yespress.io/elevatebio
Published by YesPress — https://yespress.io
Last updated: 2026-10-16